Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe are a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients living with severe autoimmune diseases. Our lead clinical-stage candidate, claseprubart, is a monoclonal antibody that is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein (“C1s”) – enabling less frequent and more convenient self-administered subcutaneous (“S.C.”) injections suitable for a pre-filled pen.
In the company’s own words · 10-K filed Mar 9, 2026 · SEC EDGAR
Business segments
Q4 2024 · $1.9MThe company’s own SEC segment disclosure.
- License$1.0M53%
- License$900.0K47%
For the full year FY2025, revenue was $2.0M (−67% year on year) and net income −$162M. Its largest product in Q4 2024 (quarter ended Dec 31, 2024) was License at $1.0M, 53% of the disclosed total, just ahead of License at 47%.
Raw charts
8 series · TTMAs reported to the SEC, without any scoring.